• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Nat Turner on Using Data for New Payment Model Requirements

Video

Nat Turner, co-founder and CEO of Flatiron Health, discusses how oncologists use data to assist them in meeting the requirements in new payment models.

Nat Turner, co-founder and CEO of Flatiron Health, discusses how oncologists use data to assist them in meeting the requirements in new payment models.

Transcript (slightly modified)

How are oncologists using data to help them meet the requirements in new payment models?

There are some simple things and some complicated things. The simplest ones—our software has the care plan built-in, so the IOM [Institute of Medicine] care plan physician doesn’t have to think about it. It auto-populates an OncoEMR, you can print it right there, the patient can be in the room, and done. A lot of analytics—getting a little more complicated but very important—analytics around how many patients do I have that are potentially eligible for the episode, which of my physicians are appropriately completing the care plan for the appropriate patients?

Getting a little more sophisticated quality measures—these are very complicated measures, some of them are easy and some are pretty hard. It takes a lot of manual work if you are going to do it on your own, to be compliant and provide the data. Some of them you have to track and some of them Medicare tracks for you. We help you in both.

So, the software is basically automating the quality measure process and moving it to the more sophisticated realm is more analytics around: what is your cost of care? What are the opportunities to implement programs that could reduce cost? For example, in hospital admissions or ER visits—more deeper analytics to help you transform your practice. Those are kind of the levels.

Related Videos
Screenshot of Jennifer Vaughn, MD, in a Zoom video interview
dr amy paller
Shawn Kwatra, MD, dermatologist, John Hopkins University
Dr Laura Ferris Discusses Safety, Efficacy of JNJ-2113 in Patients with Plaque Psoriasis
Pat Van Burkleo
dr krystyn van vliet
Joshua K. Sabari, MD, NYU Langone Perlmutter Cancer Center
Imran Khan, MD, PhD, Johnson & Johnson
dr amy paller
Martin Dahl, PhD, senior vice president, AnaptysBio
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.